Professor Rongen's research mission is to translate preclinical cardiovascular discoveries to humans, in order to facilitate clinical implementation. In his research, he aims to increase our understanding of cardiovascular pathophysiology in humans in order to improve individualized cardiovascular pharmacotherapy. His particular research interests are: clinical pharmacology of (cardiovascular) drugs, in particular in relation to regulation of vascular tone, interference with adenosine signaling and ischemia-reperfusion injury.
Professor Rongen got his PhD in clinical pharmacology of purines. After that, he had a post-doc position at the department of Cardiology, Mount Sinai Hospital, Toronto. He obtained a specialization in General Internal Medicine (certified in 2000), in Vascular Medicine and in Clinical Pharmacology.
He was appointed Professor in Translational Cardiovascular Research in 2011. Prof Rongen is Chair of the research theme 'Cardiovascular Diseases'. He is board member of the Dutch Society of Clinical Pharmacology and Biopharmacy, co-organizer of the yearly Dutch Medicines Days (FIGON) and member of the executive committee of the European Association of Clinical Pharmacology and Therapeutics.